EXHIBIT 99.1


            Abiomed Receives Conditional FDA Approval for
           Impella 2.5 Pivotal Study at up to 150 Hospitals

             Inclusion Criteria Expanded for Pivotal Study


    DANVERS, Mass.--(BUSINESS WIRE)--Aug. 30, 2007--Abiomed, Inc.
(NASDAQ: ABMD) today announced it has received conditional approval
from the U.S. Food and Drug Administration (FDA) to begin its pivotal
clinical trial in the United States for the Impella(R) 2.5 Circulatory
Support System. This approval is the result of the submission of the
clinical results of the safety pilot clinical trial and is conditional
upon the Company's submission of additional information to the FDA
over the next 45 days. The pivotal study will determine the safety and
effectiveness of the Impella 2.5 as compared to optimal medical
management with an Intra-Aortic Balloon Pump (IABP) during "high-risk"
angioplasty procedures. The study inclusion criteria have been
extended to include patients with triple vessel disease with low
ejection fraction. The study is approved under category B2 status and
the trial sites are eligible for full reimbursement from the Centers
for Medicare and Medicaid Services (CMS).

    "We are pleased to receive conditional approval from the FDA to
start this pivotal study, and remain confident in our parallel
regulatory approval path for the 510(k) clearance of the Impella 2.5.
We have submitted an additional pivotal study focused on acute
myocardial infarction patients treated with the Impella 2.5 as
compared to optimal medical management," stated Michael R. Minogue,
Chairman, President and CEO of Abiomed. "One of our primary lessons
from Europe is that high-risk angioplasty provides the optimal patient
experience and builds customer confidence in the ability of Impella.
This high-risk angioplasty study is key to our strategy for the U.S.
launch of Impella."

    "Based on the outstanding success of the pilot trial, we are very
encouraged that the Impella 2.5 will be an important tool to improve
the safety of high-risk percutaneous coronary intervention (PCI) cases
and are anxious to validate this in a trial compared to intra-aortic
balloon pump use," stated William O'Neill, National Principal
Investigator for the pilot and pivotal studies of the Impella 2.5, and
Professor and Executive Dean for Clinical Affairs, Division of
Cardiology at the Leonard M. Miller School of Medicine at the
University of Miami.

    The randomized study, at up to 150 hospitals, will compare 327
Impella 2.5 patients to 327 IABP patients and is comprised of two arms
made up of patients receiving the Impella 2.5 for up to five days as a
left ventricular assist device (VAD) and patients receiving IABP
therapy. Following Institutional Review Board (IRB) approval at each
participating hospital and requisite training, the Company plans to
ship Impella 2.5 disposables and Impella consoles to the pivotal
sites. This high-risk angioplasty pivotal trial alone represents a
revenue opportunity for Abiomed of more than $20 million.

    The clinical experience to-date with Impella 2.5 has been
favorable, including its recently completed U.S. safety pilot clinical
trial. The technology is now approved in more than 40 countries, and
is available in Europe under the CE Mark. Impella has been the subject
of more than 20 peer reviewed publications including the April 2006
American Journal of Cardiology (Volume 97, Issue 7) publication on
high-risk angioplasty. The market for percutaneous coronary
intervention, which includes high-risk patients, provides a
significant opportunity for Abiomed and represents the highest
individual utilization for IABPs. More than 20,000 IABPs are used per
year in the U.S. for PCI(1), which translates to an addressable
opportunity for the Impella 2.5 of more than $400 million in yearly
revenue for this indication alone.

    The Impella 2.5 is a left percutaneous device inserted while in
the cath-lab, which provides patients with up to 2.5 liters of blood
flow per minute. It is the world's smallest VAD and has been used to
treat conditions such as acute myocardial infarction (heart attack),
cardiogenic shock, and low output syndrome under CE Mark approval in
Europe. Due to a rise in conditions such as triple vessel disease in
patients with poor cardiac function, which is caused by coronary
vessel blocks in three vessels of the heart, the Impella 2.5 provides
a new treatment option that aims to improve patient outcomes.

    Abiomed plans to hold a conference call in the future to provide
an update on the Impella clinical study strategy and details of the
pivotal protocols.

    ABOUT ABIOMED

    Based in Danvers, Massachusetts, Abiomed, Inc., is a leading
provider of medical devices that provide circulatory support to acute
heart failure patients across the continuum of care in heart recovery.
Our products are designed to enable the heart to rest, heal and
recover by improving blood flow and/or performing the pumping of the
heart. For additional information please visit: www.abiomed.com.

    FORWARD-LOOKING STATEMENTS

    This Release contains forward-looking statements, including
statements regarding development of Abiomed's existing and new
products, the Company's progress toward commercial growth, and future
opportunities. The Company's actual results may differ materially from
those anticipated in these forward-looking statements based upon a
number of factors, including the Company's ability to provide the FDA
with the additional information it has requested, the results of the
Company's pivotal study, uncertainties associated with development,
testing and related regulatory approvals, anticipated future losses,
complex manufacturing, high quality requirements, dependence on
limited sources of supply, competition, technological change,
government regulation, future capital needs and uncertainty of
additional financing, and other risks and challenges detailed in the
Company's filings with the Securities and Exchange Commission,
including the Annual Report filed on Form 10-K and recently filed Form
10-Q. Readers are cautioned not to place undue reliance on any
forward-looking statements, which speak only as of the date of this
Release. The Company undertakes no obligation to publicly release the
results of any revisions to these forward-looking statements that may
be made to reflect events or circumstances that occur after the date
of this Release or to reflect the occurrence of unanticipated events.

    (1) Cohen M and al. Results of Benchmark Registry. Eur.Heart J.
2003 Oct;24(19):1763-70.


    CONTACT: Abiomed, Inc.
             Daniel J. Sutherby, 978-646-1812
             Chief Financial Officer
             ir@abiomed.com
             or
             Liza Heapes, 978-646-1668
             Media Relations
             mediarelations@abiomed.com
             or
             Brodeur
             Elizabeth Dumm, 617-817-7951
             Media Relations
             edumm@brodeur.com